# A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

> **NCT04492488** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Miracogen Inc.** · enrollment: 129 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Advanced or Metastatic Gastric Cancer
- Advanced or Metastatic Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** MRG002

## Key facts

- **NCT ID:** NCT04492488
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-24
- **Primary completion:** 2022-10-18
- **Final completion:** 2024-12-31
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492488, "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04492488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*